Core Laboratories Inc. /DE/

For the period ended Jun 30, 2025. Filed Jul 25, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 25, 2025

CLB$9.03+2.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets at June 30, 2025 (Unaudited) and December 31, 2024

CONSOLIDATED BALANCE SHEETS

	June 30,2025	December 31,2024
(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$31,188	$19,157
Accounts receivable, net of allowance for credit losses of $4,599 and $3,192 at 2025 and 2024, respectively	113,909	111,761
Inventories	59,773	59,402
Prepaid expenses	10,516	10,176
Income taxes receivable	14,043	15,594
Other current assets	8,248	10,516
TOTAL CURRENT ASSETS	237,677	226,606
PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $319,265 and $314,317 at 2025 and 2024, respectively	97,927	97,063
RIGHT OF USE ASSETS	55,116	56,488
INTANGIBLES, net of accumulated amortization and impairment of $19,405 and $19,326 at 2025 and 2024, respectively	6,170	6,403
GOODWILL	99,996	99,445
DEFERRED TAX ASSETS, net	70,479	69,613
OTHER ASSETS	34,746	34,788
TOTAL ASSETS	$602,111	$590,406
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$41,699	$34,549
Accrued payroll and related costs	25,319	22,901
Taxes other than payroll and income	3,623	7,106
Unearned revenues	9,115	9,332
Operating lease liabilities	11,508	10,690
Income taxes payable	4,385	4,851
Other current liabilities	9,123	8,157
TOTAL CURRENT LIABILITIES	104,772	97,586
LONG-TERM DEBT, net	124,613	126,111
LONG-TERM OPERATING LEASE LIABILITIES	42,420	43,343
DEFERRED COMPENSATION	29,639	31,115
DEFERRED TAX LIABILITIES, net	11,482	13,783
OTHER LONG-TERM LIABILITIES	21,882	20,732
COMMITMENTS AND CONTINGENCIES
EQUITY:
Preference stock, 6,000,000 shares authorized, $0.01 par value; none issued or outstanding	—	—
Common stock, 200,000,000 shares authorized, $0.01 par value, 46,966,868 issued and 46,536,790 outstanding at 2025; 46,966,868 issued and 46,826,820 outstanding at 2024	470	470
Additional paid-in capital	112,763	109,547
Retained earnings	159,824	150,280
Accumulated other comprehensive income (loss)	(5,957)	(5,769)
Treasury stock (at cost), 430,078 and 140,048 shares at 2025 and 2024, respectively	(5,817)	(2,537)
Total Core Laboratories Inc. shareholders' equity	261,283	251,991
Non-controlling interest	6,020	5,745
TOTAL EQUITY	267,303	257,736
TOTAL LIABILITIES AND EQUITY	$602,111	$590,406

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.